Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 17,001 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ELEVATE Clear all
Completed Not applicable Interventional Results available

AXIOS™ for Gallbladder Drainage as an Alternative to Percutaneous Drainage IDE

NCT03767881
View directory record Official record
Conditions
Cholecystitis, Acute
Interventions
AXIOS(TM) Stent and Electrocautery Enhanced Delivery System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Aurora, Colorado • Atlanta, Georgia • Fort Wayne, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 23, 2026, 2:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

WatchPAT Compared to PSG at 8500'

NCT04249011
View directory record Official record
Conditions
Sleep Disorder; Breathing-Related
Interventions
Not listed
Lead sponsor
Itamar-Medical, Israel
Industry
Eligibility
17 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Woodland Park, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 23, 2026, 2:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Simulation on PALS Training

NCT00562744
View directory record Official record
Conditions
Pediatric Housestaff
Interventions
Simulation
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2007 · Synced Oct 23, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

NCT02471144
View directory record Official record
Conditions
Chronic Severe Plaque-type Psoriasis
Interventions
Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 23, 2026, 2:18 PM EDT
Completed Not applicable Interventional Results available

Implementing a Hospital-Based Walking Program (STRIDE): Function QUERI 2.0

NCT04868656
View directory record Official record
Conditions
Early Ambulation
Interventions
Implementation Strategy: Foundational Support, Implementation Strategy: Enhanced Support
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 23, 2026, 2:18 PM EDT
Terminated No phase listed Observational

Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy

NCT00471653
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Thrombocytopenia
Interventions
temozolomide, comparative genomic hybridization, polymorphism analysis, laboratory biomarker analysis, pharmacological study, radiation therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Duarte, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 23, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Adults Evaluating PF-07202954

NCT04857437
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Liver Fibrosis
Interventions
PF-07202954 Repeat Dose, PF-07202954 Single Dose, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 23, 2026, 2:18 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma

NCT00028795
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
202
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 150 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2014 · Synced Oct 23, 2026, 2:18 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT04551677
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 84 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 23, 2026, 2:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Caries Detection With Two Different Caries Detecting Devices

NCT06152081
View directory record Official record
Conditions
Caries,Dental
Interventions
LumiCare rinse, QLF Inspektor Pro Imaging
Device
Lead sponsor
Tufts University
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 23, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.

NCT06719219
View directory record Official record
Conditions
Staphylococcus (S.) Aureus Infection
Interventions
LTB-SA7, Placebo
Biological
Lead sponsor
LimmaTech Biologics AG
Industry
Eligibility
18 Years to 50 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 23, 2026, 2:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Replication of the The Multi-Media Social Skills Project for Adolescents With Autism Spectrum Disorders

NCT01836965
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Social Skills Intervention
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
13 Years to 17 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 23, 2026, 2:18 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

NCT07493265
View directory record Official record
Conditions
Narcolepsy
Interventions
E2086, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
17
States / cities
Santa Ana, California • Brandon, Florida • Medley, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 23, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Trial of Yellow Fever Inactivated Vaccine

NCT00995865
View directory record Official record
Conditions
Yellow Fever
Interventions
XRX-001 Inactivated yellow fever vaccine, Placebo
Biological
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 23, 2026, 2:18 PM EDT
Terminated Phase 1 Interventional Results available

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

NCT02483000
View directory record Official record
Conditions
Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present, Diffuse Large B-Cell Lymphoma, Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory Mature B-Cell Non-Hodgkin Lymphoma
Interventions
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Clearing Agent, Cytarabine, Etoposide, Indium In 111-DOTA-Biotin, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Yttrium Y 90-DOTA-Biotin
Biological · Procedure · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 23, 2026, 2:18 PM EDT
Terminated Phase 2 Interventional Results available

Investigation of Corticosteroid Versus Placebo Injection in Patients With Syndesmotic Ligament Injury or High Ankle Sprain

NCT02892500
View directory record Official record
Conditions
Ankle Injuries
Interventions
bupivacaine hydrochloride and betamethasone sodium phosphate, bupivacaine hydrochloride
Drug
Lead sponsor
Sanford Health
Other
Eligibility
16 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 23, 2026, 2:18 PM EDT
Recruiting No phase listed Observational

Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care

NCT06482073
View directory record Official record
Conditions
Lung Carcinoma, Metastatic Malignant Neoplasm in the Lung
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 23, 2026, 2:18 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Preliminary Efficacy Study of V404 PDS in Uveitis

NCT02125266
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Intermediate
Interventions
V404
Drug
Lead sponsor
Forsight Vision4
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Golden, Colorado • Atlanta, Georgia • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2016 · Synced Oct 23, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation

NCT03130556
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Glasdegib, High Fat, High Calorie Meal, Rabeprazole
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 23, 2026, 2:18 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults

NCT07757802
View directory record Official record
Conditions
HIV
Interventions
DV901-NP, DV902-NP, CH505 TF mRNA-gp160, CH505 w24 mRNA-gp160, ACU-026-001-1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
8
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 2:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.

NCT00186537
View directory record Official record
Conditions
Insulin Resistance, Hypertriglyceridemia
Interventions
Rosiglitazone, Fenofibrate, Weight Loss
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 23, 2026, 2:18 PM EDT
Recruiting Phase 2 Interventional

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT04169737
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Obinutuzumab, Venetoclax
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 2:18 PM EDT
Withdrawn Not applicable Interventional

Repetitive Transcranial Magnetic Stimulation (rTMS) Self-Referential Processing (rTMS-SRP)

NCT04068857
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
rTMS
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 23, 2026, 2:18 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)

NCT02634645
View directory record Official record
Conditions
Barrett's Esophagus, Esophageal Cancer
Interventions
Endoscopic eradication therapies (EET), Esophagectomy, Chemotherapy, Radiation
Procedure · Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 23, 2026, 2:18 PM EDT